HCM
Price
$15.72
Change
-$0.07 (-0.44%)
Updated
Sep 26, 10:30 AM (EDT)
Capitalization
2.67B
49 days until earnings call
SFOSF
Price
$3.50
Change
+$0.35 (+11.11%)
Updated
Sep 22 closing price
Capitalization
10.88B
Interact to see
Advertisement

HCM vs SFOSF

Header iconHCM vs SFOSF Comparison
Open Charts HCM vs SFOSFBanner chart's image
HUTCHMED (China)
Price$15.72
Change-$0.07 (-0.44%)
Volume$414
Capitalization2.67B
Shanghai Fosun Pharmaceutical Group
Price$3.50
Change+$0.35 (+11.11%)
Volume$300
Capitalization10.88B
HCM vs SFOSF Comparison Chart in %
Loading...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. SFOSF commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a StrongBuy and SFOSF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (HCM: $15.79 vs. SFOSF: $3.50)
Brand notoriety: HCM and SFOSF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 79% vs. SFOSF: 34%
Market capitalization -- HCM: $2.67B vs. SFOSF: $10.88B
HCM [@Pharmaceuticals: Generic] is valued at $2.67B. SFOSF’s [@Pharmaceuticals: Generic] market capitalization is $10.88B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 1 FA rating(s) are green whileSFOSF’s FA Score has 2 green FA rating(s).

  • HCM’s FA Score: 1 green, 4 red.
  • SFOSF’s FA Score: 2 green, 3 red.
According to our system of comparison, SFOSF is a better buy in the long-term than HCM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 3 TA indicator(s) are bullish while SFOSF’s TA Score has 2 bullish TA indicator(s).

  • HCM’s TA Score: 3 bullish, 6 bearish.
  • SFOSF’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, SFOSF is a better buy in the short-term than HCM.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а -9.51% price change this week, while SFOSF (@Pharmaceuticals: Generic) price change was +11.11% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.68%. For the same industry, the average monthly price growth was +25.26%, and the average quarterly price growth was +68.42%.

Reported Earning Dates

HCM is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.68% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SFOSF($10.9B) has a higher market cap than HCM($2.67B). SFOSF has higher P/E ratio than HCM: SFOSF (20.41) vs HCM (5.96). SFOSF YTD gains are higher at: 94.412 vs. HCM (9.577). SFOSF has higher annual earnings (EBITDA): 9.49B vs. HCM (38M). SFOSF has more cash in the bank: 15.6B vs. HCM (1.37B). HCM has less debt than SFOSF: HCM (93.4M) vs SFOSF (37B). SFOSF has higher revenues than HCM: SFOSF (40.1B) vs HCM (602M).
HCMSFOSFHCM / SFOSF
Capitalization2.67B10.9B25%
EBITDA38M9.49B0%
Gain YTD9.57794.41210%
P/E Ratio5.9620.4129%
Revenue602M40.1B2%
Total Cash1.37B15.6B9%
Total Debt93.4M37B0%
FUNDAMENTALS RATINGS
HCM vs SFOSF: Fundamental Ratings
HCM
SFOSF
OUTLOOK RATING
1..100
5695
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1979
PRICE GROWTH RATING
1..100
5836
P/E GROWTH RATING
1..100
9921
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SFOSF's Valuation (28) in the null industry is somewhat better than the same rating for HCM (89) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew somewhat faster than HCM’s over the last 12 months.

SFOSF's Profit vs Risk Rating (100) in the null industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.

HCM's SMR Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for SFOSF (79) in the null industry. This means that HCM’s stock grew somewhat faster than SFOSF’s over the last 12 months.

SFOSF's Price Growth Rating (36) in the null industry is in the same range as HCM (58) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.

SFOSF's P/E Growth Rating (21) in the null industry is significantly better than the same rating for HCM (99) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew significantly faster than HCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMSFOSF
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
50%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
52%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
45%
Advances
ODDS (%)
Bullish Trend 15 days ago
74%
Bullish Trend 23 days ago
57%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PTSGX19.25N/A
N/A
Touchstone Sands Capital Select Growth Z
EITVX43.29N/A
N/A
Eaton Vance Tx-Mgd Value I
NSCRX53.55N/A
N/A
Nuveen Small-Cap Value Opps I
TIBIX31.98N/A
N/A
Thornburg Investment Income Builder I
BGGIX12.11N/A
N/A
William Blair Global Leaders R6

SFOSF and

Correlation & Price change

A.I.dvisor tells us that SFOSF and CANN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SFOSF and CANN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SFOSF
1D Price
Change %
SFOSF100%
N/A
CANN - SFOSF
21%
Poorly correlated
-2.68%
HCM - SFOSF
21%
Poorly correlated
-0.57%
MSTH - SFOSF
21%
Poorly correlated
N/A
SGIOF - SFOSF
11%
Poorly correlated
N/A
RAFA - SFOSF
9%
Poorly correlated
-10.00%
More